EPO and Brazilian Patent Office launch new PPH agreement

In Insights

16 October, 2017
EPO and Brazilian Patent Office launches new PPH agreement

The ever expanding PPH (Patent Prosecution Highway) network has once again gotten a new addition, and as always AWA Point sums up the new expansions and arising possibilities. 

To recall, for a given PPH agreement the PPH allows for requesting accelerated examination at the one office participating in this agreement based on the search results and a set of claims accepted for grant in an analogous application at the other participating office.

Most recently, European patent applicants are offered a new possibility of speeding up and simplifying examination of their patent applications. Namely, the EPO (European Patent Office) has just announced the signing of a new PPH agreement – this time with the IP office of Brazil. This new PPH agreement will, according to the EPO, enter into force in the beginning of 2018. The announcement may be found here. AWA Point will inform its readers of the actual date of the entry into force.

Furthermore, on 1 October 2017, the PPH agreement between the EPO and the Eurasian Patent Office (EAPO)entered into force. The agreement applies to both national and to PCT work products. The EPO’s notification of entry into force may be found here.

An overview of existing and working agreements under the Global PPH at the time of writing can be seen on the PPH website compiled by the Japanese Patent Office, JPO, here.

You may also be interested in:

Navigating Meta’s shifted Moderation Model: What brand owners should prepare for

Meta is shifting away from third-party fact-checking and adopting the Community Notes Model, first introduced by X (formerly Twitter) under Elon Musk’s

Read more...

Companies with IP generate at least 23.8% more revenue according to latest EU report

The report ‘The Intellectual Property Rights and Firm Performance in the European Union’ was published last month and analyses

Read more...

European Commission reports show misuse of divisionals can in itself contravene EU law

In November last year, I was interviewed about the European Commission’s €462.6 million fine against pharmaceutical giant Teva and

Read more...

Mobile Sliding Menu